ContraVir Pharmaceuticals Announces $9.0 Million Private Placement
Sichenzia Ross Friedman Ference LLP Advises ContraVir Pharmaceuticals on $9.0 Million Private Placement
New York, October 28, 2014 (Global Newswire) – New York based securities law firm Sichenzia Ross Friedman Ference LLP announced that it has represented ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, on a $9 million private placement consisting of Series A Convertible Preferred stock to a non-U.S investor.
Pursuant to the private placement, the Series A Preferred Stock can be converted into shares of common stock at the conversion price of $0.48 per share. The Sichenzia Ross Friedman Ference LLP team was led by partner Jeffrey J. Fessler.
About Sichenzia Ross Friedman Ference LLP
Sichenzia Ross Friedman Ference LLP is a corporate and securities law firm that provides experienced, professional representation in all matters involving the securities industry, as well as in all general corporate and litigation matters. SRFF’s clients range from start-ups to established, listed companies. They include private and public corporations, partnerships, broker-dealers, bank-affiliated broker-dealers, investment advisors, registered personnel, public and corporate customers and investors, partnerships and other entities. SRFF also advises institutional investors on transactions involving complex securities law considerations. SRFF’s practice includes the representation of clients located in the United States and throughout the world. To learn more about SRFF, visit www.srff.com, SRFF’s LinkedIn, Twitter: @SRFFLLP and Facebook pages.